Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | AHR | P35869 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | IKBKB | O14920 | 2/20 | 0.41 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13851094 | 0.88 | LMNA (0.56) | LMNATLR8ALDH1A1KDM4ENR1I2 | |
| Bromide SCHEMBL8547428 | 0.86 | LMNA (0.61) | LMNATLR8ALDH1A1KDM4ENR1I2 | |
| SCHEMBL10161427 | 0.84 | LMNA (0.46) | LMNATLR8ALDH1A1KDM4ENR1I2 | |
| SCHEMBL1983684 | 0.82 | NR1I2 (0.47) | LMNATLR8ALDH1A1KDM4ENR1I2 | |
| SCHEMBL2396549 | 0.82 | LMNA (0.44) | LMNATLR8ALDH1A1KDM4ENR1I2 | |
| SCHEMBL26978230 | 0.78 | ALDH1A1 (0.51) | LMNATLR8ALDH1A1KDM4ENR1I2 | |
| SCHEMBL15688197 | 0.77 | LMNA (0.40) | LMNATLR8ALDH1A1KDM4ENR1I2 | |
| SCHEMBL19174177 | 0.75 | LMNA (0.39) | LMNATLR8ALDH1A1KDM4ENR1I2 | |
| SCHEMBL21963176 | 0.75 | LMNA (0.55) | LMNATLR8ALDH1A1KDM4ENR1I2 | |
| SCHEMBL9644113 | 0.73 | ALDH1A1 (0.50) | LMNATLR8ALDH1A1KDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110028457-B | Isotope labeled sulfabromodimethyl pyrimidine and synthesis method thereof | 深圳出入境检验检疫局食品检验检疫技术中心 | 2023-01-20 | — | — | CN | claimed |
| CN-110028457-A | A kind of sulfabromomethazine and its synthetic method of stable isotope labeling | 深圳出入境检验检疫局食品检验检疫技术中心 | 2019-07-19 | — | — | CN | claimed |
| EP-4744661-A2 | NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| EP-4676923-A1 | BIARYLAMIDE DERIVATIVES AND THEIR USE AS PKMYT1 INHIBITORS | Cancer Research Technology Limited (GB) | 2026-01-14 | — | — | EP | disclosed |
| EP-4298092-B1 | NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-11-26 | — | — | EP | disclosed |
| US-20250304600-A1 | PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2025-10-02 | — | — | US | disclosed |
| EP-4608988-A1 | CLOSED-LOOP OPTIMIZATION OF GENERAL REACTION CONDITIONS FOR HETEROARYL SUZUKI-MIYAURA COUPLING | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-09-03 | — | — | EP | disclosed |
| EP-4267574-B1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250059174-A1 | Pharmaceutical Compounds and Compositions as C-Kit Kinase Inhibitors | ENANTA PHARM INC (US) | 2025-02-20 | — | — | US | disclosed |
| WO-2025034951-A1 | PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| US-20240327390-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2024-10-03 | — | — | US | disclosed |
| US-6506761-B1 | Compound of the invention are active as inhibitors of Thrombin and are useful in treating disease states in mammals which are characterized by abnormal thrombosis and have the following structure: | CORVAS INTERNATIONAL, INC. | 2003-01-14 | — | — | US | disclosed |
| US-6506754-B1 | Compounds as anticoagulants | CORVAS INTERNATIONAL, INC. | 2003-01-14 | — | — | US | disclosed |
| US-6506760-B1 | Compounds of the invention are active as inhibitors of Thrombin and are useful in treating disease states in mammals which are characterized by abnormal thrombosis and have the following structure: | CORVAS INTERNATIONAL, INC. | 2003-01-14 | — | — | US | disclosed |
| EP-0174272-B1 | PROCESS FOR THE PREPARATION OF DIMETHYLMALEIC ANHYDRIDE | CIBA-GEIGY AG (CH) | 1988-08-31 | — | — | EP | disclosed |
| EP-0175641-B1 | PROCESS FOR THE PREPARATION OF DIMETHYLMALEIC ANHYDRIDE | CIBA-GEIGY AG (CH) | 1988-02-24 | — | — | EP | disclosed |
| US-4644069-A | HEATING MALEIC ACID OR ANHYDRIDE WITH AN AMIDINE OR ITS SALT | CIBA-GEIGY CORPORATION (US) | 1987-02-17 | — | — | US | disclosed |
| US-4639531-A | HETEROCYCLIC AMIDINE CATALYST | CIBA-GEIGY CORPORATION (US) | 1987-01-27 | — | — | US | disclosed |
| EP-0175641-A1 | Process for the preparation of dimethylmaleic anhydride | CIBA-GEIGY AG (CH) | 1986-03-26 | — | — | EP | disclosed |
| EP-0174272-A1 | Process for the preparation of dimethylmaleic anhydride | CIBA-GEIGY AG (CH) | 1986-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327390-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | NR0B1, GRK1, GRIN1 | LMNA 610/4885TLR8 1672/4885ALDH1A1 2289/4885 |
| US-20250304600-A1 | PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS | KIT, PDGFRA, PDGFRB | LMNA 1994/4885TLR8 2986/4885ALDH1A1 1140/4885 |
| US-20250059174-A1 | Pharmaceutical Compounds and Compositions as C-Kit Kinase Inhibitors | KIT, PDGFRA, PDGFRB | LMNA 1994/4885TLR8 2986/4885ALDH1A1 1140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.